Staurosporine inhibits a variety of kinases including PKA (Ki=7.0 nM), PKG (Ki=8.5 nM), MLCK (Ki=1.3 nM), PKC (Ki=0.7 nM), CaMK (IC50=20 nM), tyrosine kinases (IC50=70 nM) and phosphorylase kinase (IC50=0.5 nM). Inhibition is via interaction with the ATP binding site. It induces PKC translocation and augments PMA-induced ornithine decarboxylase. Activates a Bcl-2-regulated apoptosis pathway. At 1µM, induced apoptosis in CHO cells.
Inhibits topoisomerase II directly by blocking transfer of phosphodiester bonds from DNA to active site tyrosine.
Purity: ≥99% (TLC)
Long Term Storage: -20°C
Appearance: Off-white to green powder
Hazard: MAY BE CARCINOGENIC.TOXIC.
Handling: Protect from light and moisture.
Use/Stability: Store, as supplied, at 0-4°C for up to 1 year. Store solutions at -20°C for up to 3 months.
Solubility: Soluble in DMSO (25mg/ml), dimethyl formamide (25mg/ml), DMSO or ethyl acetate. Slightly soluble in chloroform and methanol. Insoluble in water.
Biomol Staurosporine BML-EI156-0100 100 ug -20°C 1113
Biomol Staurosporine BML-EI156-1000 1 mg -20°C 6846